No UTI risk with most of the SGLT-2 inhibitors: Study
SGLT2 inhibitors do not increase the risk for urinary tract infections in people with type 2 diabetes; however, high doses of dapagliflozin may be an exception, according to findings published in the Canadian Medical Association Journal.

“There is a popular misconception that SGLT2 inhibitors cause urinary tract infections, especially since they clearly cause more genital infections, this study contributes to the growing body of evidence that shows that SGLT2 inhibitors are likely not causing urinary tract infections, but rather the increased urinary glucose concentration may be somehow linked to infection severity”, the lead author of the study has said.

The authors conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes and investigated whether there is a dose-response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo.

Most mixed-treatment comparisons revealed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo with active comparators, with empagliflozin at both low and high doses, and with low-dose ertugliflozin.

Read in detail about the research here: